Hong Kong-based OrbusNeich Medical and P+F Products + Features have signed an agreement for the exclusive distribution and manufacturing of various minimally invasive heart valve products in the Asia-Pacific region.
The companies plan to cover countries, including China, Japan, Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia, and New Zealand.
The deal includes a series of P+F’s innovative minimally invasive heart valve products premounted on the delivery system, using its dry valve technology.
As part of the agreement, the portfolio, comprising the TricValve Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather Valve, along with transcatheter solutions for pulmonary and mitral valve disease, and endovascular grafts will be distributed.
The TricValve Transcatheter Bicaval Valves consists of two self-expanding biological valves used for treating patients with hemodynamically relevant tricuspid insufficiency and caval reflux.
The system is aimed at patients who are at extreme risk or unsuitable for open-heart surgery.
Designed to treat severe aortic stenosis in patients with a medium to high risk for open-heart surgery, the Vienna Aortic Self-Expandable Transcatheter Valve replaces the native aortic valve. The procedure does not require concomitant surgical removal.
P+F CEO Katharina Kiss said: “My mission as a cardiologist is not only to save lives but to ensure the maximum quality of life for each of our patients and I am convinced that with the joint efforts of this newly founded Asian joint venture, we will be able to revolutionise the medical landscape.”
The TricValve Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather Valve are awaiting CE mark approval.
OrbusNeich chairman, president, and CEO David Chien said: “Our unique product line for percutaneous transcatheter based therapeutics will result in significant improvement of health-related quality of life to our patients, which is an important measure of procedural success in the elderly.”
